Drug intelligence / Profile preview

IL-KTM

Development stage: Preclinical
Lead developer: PARAS Biopharma
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

IL-KTM (also known as PB(RA)-2010) is a biosimilar recombinant protein candidate developed by Paras Biopharmaceuticals. It is a biosimilar of Kineret (anakinra), functioning as a recombinant human interleukin-1 receptor antagonist (IL-1RA). The drug is a non-glycosylated version of IL-1RA produced in genetically modified E. coli, consisting of 153 amino acids with a molecular mass of 17.3 kDa. By binding to the IL-1 receptor, IL-KTM blocks the biological activity of interleukin-1 (IL-1), a key mediator of inflammation and driver of autoinflammatory diseases. It is currently in preclinical development for the treatment of rheumatoid arthritis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA).

Brand names: IL-KTM
Other names: anakinra biosimilar

Targets

IL-1R (Interleukin-1 receptor type 1 (IL-1R1))

Beyond the preview

Go deeper on IL-KTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-KTM.

Explore the full profile